The inhibitory effect of anandamide on oxytocin and vasopressin secretion from neurohypophysis is mediated by nitric oxide

Regulatory Peptides

Volumn 188, Issue , 2013, Pages 31-39

  Luce, Valeria ^a   Fernandez Solari, Javier ^b   Rettori, Valeria ^a   De Laurentiis, Andrea ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cannabinoid receptors; Endocannabinoids; Nitric oxide synthase

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CAPSAZEPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYTOCIN; VANILLOID RECEPTOR 1; VASOPRESSIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MALE; NEUROHYPOPHYSIS; NONHUMAN; OXYTOCIN RELEASE; PRIORITY JOURNAL; RAT; VASOPRESSIN RELEASE;

CANNABINOID RECEPTORS; ENDOCANNABINOIDS; NITRIC OXIDE SYNTHASE;

ANIMALS; ARACHIDONIC ACIDS; ENDOCANNABINOIDS; MALE; NITRIC OXIDE; OXYTOCIN; PITUITARY GLAND, POSTERIOR; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; TISSUE CULTURE TECHNIQUES; VASOPRESSINS;

EID: 84891075470     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2013.12.004     Document Type: Article

References (75)

1. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function and regulation. Physiol Rev 2001, 81:629-683.
2. Stoop R. Neuromodulation by oxytocin and vasopressin. Neuron 2012, 76:142-159.
3. Leng G., Ludwig M. Neurotransmitters and peptides: whispered secrets and public announcements. J Physiol 2008, 586:5625-5632.
4. Herman J.P., Flak J., Jankord R. Chronic stress plasticity in the hypothalamic paraventricular nucleus. Progress in Brain Research 2008, vol. 170:353-364. Elsevier, Oxford, U.K. I.D. Neumann, R. Landgraf (Eds.).
5. Smith A.S., Wang Z. Salubrious effects of oxytocin on social-stress induced deficits. Horm Behav 2012, 61:320-330.
6. Antunes-Rodrigues J., De Castro M., Elias L.L.K., Valença M.M., McCann S.M. Neuroendocrine control of body fluid metabolism. Physiol Rev 2004, 84:169-208.
7. Aguilera G., Subburaju S., Young S., Chen J. The parvocellular vassopresinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Progress in Brain Research 2008, vol. 170:29-39. Elsevier, Oxford, U.K. I.D. Neumann, R. Landgraf (Eds.).
8. Brown C.H., Bains J.S., Ludwig M., Stern J.E. Physiological regulation of magnocellular neurosecretory cell activity: integration of intrinsic, local and afferent mechanisms. J Neuroendocrinol 2013, 25:678-710.
9. Leng G., Brown C.H., Russell J.A. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol 1999, 57:625-655.
10. Miyagawa A., Okamura H., Ibata Y. Coexistence of oxytocin and NADPH-diaphorase in magnocellular neurons of the paraventricular and supraoptic nuclei of the rat hypothalamus. Neurosci Lett 1994, 171:13-16.
11. Xiao M., Ding J., Wu L., Han Q., Wang H., Zuo G., Hu G. The distribution of neural nitric oxide synthase-positive cerebrospinal fluid-contacting neurons in the third ventricular wall of male rats and coexistence with vasopressin or oxytocin. Brain Res 2005, 1038:150-162.
12. Stern J.E., Ludwig M. NO inhibits supraoptic oxytocin and vasopressin neurons via activation of GABAergic synaptic inputs. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1815-R1822.
13. Rettori V., Canteros G., Reynoso R., Gimeno M., McCann S.M. Oxytocin stimulates the release of luteinizing hormone-releasing hormone from medial basal hypothalamic explants by releasing nitric oxide. Proc Natl Acad Sci 1997, 94:2741-2744.
14. Kadekaro M., Terrell M.L., Liu H., Gestl S., Bui V., Summy-Long J.Y. Effects of L-NAME on cerebral, vasopressin, oxytocin, and blood pressure responses in hemorrhaged rats. Am J Physiol 1998, 274:1070-1077.
15. Summy-Long J., Bui V., Mantz S., Koehler E., Weisz J., Kadekaro M. Central inhibition of nitric oxide synthase preferentially augments release of oxytocin during dehydration. Neurosci Lett 1993, 152:190-193.
16. Stern J.E., Zhang W. Cellular sources, targets and actions of constitutive nitric oxide in the magnocellular neurosecretory system of the rat. J Physiol 2005, 562:725-744.
17. De Laurentiis A., Fernandez-Solari J.J., Mohn C., Burdet B., Zorrilla Zubilete M., Rettori V. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor alpha induced by lipopolysaccharide. J Neuroimmunol 2010, 221:32-41.
18. Vincent S.R., Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992, 46:755-784.
19. Bredt D.S., Hwang P.M., Snyder S.H. Localization of nitric oxide synthase indicating a neural role of nitric oxide. Nature 1990, 347:768-770.
20. Sagar S.M., Ferreiro D.M. NADPH diaphorase activity in the posterior pituitary: relation to neuronal function. Brain Res 1987, 400:348-352.
21. Lutz-Bucher B., Koch B. Evidence for an inhibitory effect of nitric oxide on neuropeptide secretion from isolated neural lobe of the rat pituitary gland. Neurosci Lett 1994, 165:48-50.
22. De Laurentiis A., Pisera D., Duvilanski B., Rettori V., Lasaga M., Seilicovich A. Neurokinin A inhibits oxytocin and GABA release from GABA release from the posterior pituitary by stimulating nitric oxide synthase. Brain Res Bull 2000, 53:325-330.
23. Mechoulam R., Parker L.A. The endocannabinoid system and the brain. Annu Rev Psychol 2013, 64:6.1-6.27.
24. Katona I., Freund T.F. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 2012, 35:529-558.
25. Fowler C.J. Anandamide uptake explained?. Trends Pharmacol Sci 2012, 33:181-185.
26. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 2006, 30:S13-S18.
27. González S., Manzanares J., Berrendero F., Wenger T., Corchero J., Bisogno T., Romero J., Fuentes J.A., Di Marzo V., Ramos J.A., Fernández-Ruiz J. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. Neuroendocrinology 1999, 70:137-145.
28. 1 cannabinoid receptors in the anterior lobe of the pituitary gland. J Neuroendocrinol 1999, 11:873-878.
29. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grübler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., Stalla G.K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 2001, 86:2687-2696.
30. Murphy L.L., Muñoz R.M., Adrian B.A., Villanúa M.A. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 1998, 5:432-446.
31. 2 receptors: immunohistochemical localization in rat brain. Brain Res 2006, 1071:10-23.
32. 2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 2012, 26:92-103.
33. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000, 129:227-230.
34. Cristino L., De Petrocellis L., Pryce G., Baker D., Guglielmotti V., Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006, 139:1405-1415.
35. Guo A., Vulchanova L., Wang J., Li X., Elde R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999, 11:946-958.
36. Sudbury J.R., Ciura S., Sharif-Naeini R., Bourque C.W. Osmotic and thermal control of magnocellular neurosecretory neurons-role of an N-terminal variant of TRPV1. Eur J Neurosci 2010, 32:2022-2030.
37. van der Stelt M., Di Marzo V. Endovanilloids: putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004, 271:1827-1834.
38. 2+ signalling. Cell Calcium 2009, 45:611-624.
39. Di S., Boudaba C., Popescu I.R., Weng F., Harris C., Marcheselli V.L., Bazan N.G., Tasker J.G. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J Physiol 2005, 569:751-760.
40. Scorticati C., Fernández-Solari J., De Laurentiis A., Mohn C., Prestifillipo J.P., Lasaga M., Seilicovich A., McCann S.M., Rettori V. The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc Natl Acad Sci U S A 2004, 101:11891-11896.
41. Scorticati C., Mohn C., De Laurentiis A., Vissio P., Fernández-Solari J., Prestifillipo J.P., Seilicovich A., McCann S.M., Rettori V. The effect of anandamide on prolactin secretion is modulated by estrogen. Proc Natl Acad Sci U S A 2003, 100:2134-2139.
42. Fernández-Solari J., Scorticati C., Mohn C., De Laurentiis A., Billi S., Franchi A., McCann S.M., Rettori V. Alcohol inhibits luteinizing hormone-releasing hormone release by activating the endocannabinoid system. Proc Natl Acad Sci U S A 2004, 101:3264-3268.
43. Rettori V., Wenger T., Snyder G., Dalterio S., McCann S.M. Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology 1988, 47:498-503.
44. Sofia R.D., Knobloch L.C., Harakal J.J., Erikson D.J. Comparative diuretic activity of delta 9-tetrahydrocannabinol, cannabidiol, cannabinol and hydrochlorothiazide in the rat. Arch Int Pharmacodyn Ther 1977, 225:77-87.
45. Tyrey L., Murphy L.L. Inhibition of suckling-induced milk ejections in the lactating rat by delta 9-tetrahydrocannabinol. Endocrinology 1988, 123:469-472.
46. Butovsky E., Juknat A., Elbaz J., Shabat-Simon M., Eilam R., Zangen A., Altstein M., Vogel Z. Chronic exposure to delta 9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas. Mol Cell Neurosci 2006, 31:795-804.
47. Di S., Malcher-Lopes R., Marcheselli V.L., Bazan N.G., Tasker J.G. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and GABA inputs to hypothalamic magnocellular neurons. Endocrinology 2005, 146:4292-4301.
48. Bredt D.S., Snyder S.H. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci U S A 1989, 86:9030-9033.
49. Caldwell H.K., Young W.S. Oxytocin and vasopressin: genetics and behavioural implications. Handbook of Neurochemistry and, Molecular Neurobiology 2006, 573-607. Springer-Verlag Berlin Heidelberg (Ed.).
50. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabiniod receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
51. McDonald N.A., Kumiski J.B., Naderi N., Schwab Y., Pittman Q.J. Endogenous modulators of synaptic transmission: cannabinoid regulation in the supraoptic nucleus. Prog Brain Res 2008, 170:129-136.
52. 1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 2004, 47:593-603.
53. Häring M., Guggenhuber S., Lutz B. Neuronal populations mediating the effects of endocannabinoids on stress and emotionality. Neuroscience 2012, 204:145-158.
54. Jerman J.C., Gray J., Brough S.J., Ooi L., Owen D., Davis J.B., Smart D. Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors. Br J Anaesth 2002, 89:882-887.
55. Moreira F.A., Aguiar D.C., Guimarães F.S. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 2007, 52:958-965.
56. Starowicz K., Maione S., Cristino L., Palazzo E., Marabese I., Rossi F., de Novellis V., Di Marzo V. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci 2007, 27:13739-13749.
57. Stuenkel E.L., Nordmann J.J. Intracellular calcium and vasopressin release of rat isolated neurohypophysial nerve endings. J Physiol 1993, 468:335-355.
58. Dayanithi G., Viero C., Shibuya I. The role of calcium in the action and release of vasopressin and oxytocin from CNS neurones/terminals to the heart. J Physiol Pharmacol 2008, 59:7-26.
59. Rosso L., Mienville J.M. Pituicyte modulation of neurohormone output. Glia 2009, 57:235-243.
60. László F.A., Gálfi M., Jójárt I., Vecsernyés M., Laczi F., Maderschpach K. Neurohypophysis tissue culture as a model of hormonal activity of rat pituicytes. Proc. 4th Int. Conf. neurohypophysis, new aspects of morphology function and regulation 1989, 87-91. Oxford Univ Press, Copenhagen.
61. Kadekaro M. Nitric oxide modulation of the hypothalamo-neurohyphopyseal system. Braz J Med Biol Res 2004, 37:441-450.
62. Fimiani C., Liberty T., Aquirre A., Amin L., Ali N., Stefano G. Opiate, cannabinoid, and eicosanoid signalling converges on common intracellular pathways nitric oxide coupling. Prostaglandins Other Lipid Mediat 1999, 57:23-34.
63. Maccarrone M., van der Stelt M., Rossi A., Veldink G.A., Vliegenthart J.F., Agrò A.F. Anandamide uptake by human endothelial cells and its regulation by nitric oxide J. Biol Chem 2000, 275:13484-13492.
64. Tappaz M.L., Kakucska I., Paut L., Makara G.B. Decreased GABAergic innervation of the pituitary intermediate lobe after rostral hypothalamic cuts. Brain Res Bull 1986, 17:711-716.
65. Sladek C., Armstrong W.E. Gamma-aminobutyric acid antagonists stimulate vasopressin release from organ-cultured hypothalamo-neurohypophyseal explants. Endocrinology 1987, 120:1576-1580.
66. Crowley W.R., Armstrong W.E. Neurochemical regulation of oxytocin secretion in lactation. Endocr Rev 1992, 13:33-65.
67. Gálfi M., Janaky T., Toth R., Prohaszka G., Juhasz A., Varga C., László F.A. Effects of dopamine and dopamine-active compounds on oxytocin and vasopressin production in rat neurohypophyseal tissue cultures. Regul Pept 2001, 98:49-54.
68. Gálfi M., Radacs M., Juhasz A., László F., Molnar A., László F.A. Serotonin induced enhancement of vasopressin and oxytocin secretion in rat neurohypophyseal tissue culture. Regul Pept 2005, 127:225-231.
69. Galfi M., Balaspiri L., Toth R., Pavo I., Csajbok E., Laszlo F., Morschl E., Varga C., Laszlo F.A. Inhibitory effect of galanin on dopamine induced increased oxytocin secretion in rat neurohypophyseal tissue cultures. Regul Pept 2003, 116:35-41.
70. Radács M., Gálfi M., Juhász A., Varga Cs., Molnár A., László F., László F.A. Histamine-induced enhancement of vasopressin and oxytocin secretion in rat neurohypophyseal tissue cultures. Regul Pept 2006, 134:82-88.
71. Adams I.B., Ryan W., Singer M., Thomas B.F., Compton D.R., Razdan R.K., Martin B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 1995, 273:1172-1181.
72. Fernandez-Solari J., Prestifilippo J.P., Bornstein S., McCann S.M., Rettori V. Participation of the endocannabinoid system in the effect of TNF-α on hypothalamic release of gonadotropin-releasing hormone. Ann N Y Acad Sci 2006, 1088:238-250.
73. Herkenham M. Localization of cannabinoid receptors in brain and periphery. Cannabinoid Receptors 1995, 145-166. Academic Press, New York. R.G. Pertwee (Ed.).
74. Szallasi A., Di Marzo V. New prospective on enigmatic vanilloid receptors. Trends Neurosci 2000, 23:491-497.
75. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003, 140:790-801.